Preoperative Gabapentin for Cosmetic Breast Surgery

Sponsor
University of Puerto Rico (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05997355
Collaborator
(none)
100
2
11

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to compare postoperative pain and opioid consumption in patients who undergo cosmetic breast surgery and are treated preoperatively with gabapentin. The main questions to answer are the amount of postoperative pain on a scale of 0-10 and amount of opioids consumed postoperatively. Participants will be randomized into two groups: treatment vs no treatment. Treatment group will receive 600mg of gabapentin preopreatively. Researchers will compare treatment vs no treatment group to determine the effects of preoperative gabapentin on postoperative pain management and opioid consumption.

Condition or Disease Intervention/Treatment Phase
  • Drug: Gabapentin 600Mg Tab
N/A

Detailed Description

HYPOTHESIS We hypothesize that a single dose of preoperative gabapentin will improve postoperative pain scores and decrease postoperative opioid requirements in our study population. This will be tested by administering a preoperative dose of 600mg of gabapentin and measuring pain scores and amount of opioid consumption during the postoperative period. The study will compare two groups. Participants will be randomly assigned to one of the two groups and will consist of a treatment group and a control group. We will measure pain scores in a simple 0-10 scale and amount of opioid consumption during the first 7 days after discharge and compare them with patients who did not receive preoperative gabapentin. Our aims are to determine if gabapentin improves postoperative analgesia and reduces postoperative opioid requirements in a population undergoing cosmetic breast surgery

METHODOLOGY AND STUDY DESIGN

This study will be a randomized control trial. Participants will be randomized and divided into treatment versus no treatment group. Treatment group will be administered a dose of 600mg of gabapentin within 2 hours of surgery. Amount of postoperative opioids will be measured for 7 days, post op pain scores will be measured twice daily for 7 days. This information will be collected via postoperative questionnaires.

STUDY SUBJECTS Participants will be adult, non pregnant patients older than 18 years undergoing cosmetic breast surgery at either Hospital Oncologico Isaac Gonzalez Martinez or Hospital UPR Federico Trilla. Participants will be selected during the initial clinic visit, there will be no specific recruiting strategies. Excluded populations include minors 18 years old or less as well as pregnant females due to health concerns. Participants will be explained in detail the goal and objectives of study along with risks vs benefits. The following HIPAA identifiers will be excluded: Geographical elements, fax numbers, social security numbers, health insurance beneficiary numbers, vehicle identifiers, digital identifiers, digital attributes, IP addresses, biometric elements and full face photographic images.

VARIABLES

Primary outcomes will be the amount of postoperative pain and amount of postoperative opioid consumption. Postoperative pain will be defined and measured as a score from 1-10. Opioid consumption will be defined and measured as the amount of standard doses used in the postoperative period. Prior chronic gabapentin or opioid use will also be a variable accounted for to eliminate confounding effects of tachyphylaxis.

ANALYTIC PLAN Data will be organized in tables and analyzed with simple t-test to compare mean pain scores and amount of postoperative opioid consumption. Data will be stored within a shared google drive folder in a private excel/google sheets document. Each researcher listed in the study protocol will have access to the data individually via their own electronic devices in order to access when needed. CO-PI will administer privacy settings and provide access to each researcher. Data checks will periodically be performed to ensure data consistency.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Intervention Model Description:
Treatment with gabapentin vs no treatmentTreatment with gabapentin vs no treatment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
"Preoperative Gabapentin and Its Effects on Postoperative Analgesia in Patients Undergoing Cosmetic Breast Surgery"
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Jul 31, 2024
Anticipated Study Completion Date :
Jul 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment

Patient will be treated with preoperative gabapentin

Drug: Gabapentin 600Mg Tab
A single preoperative dose of gabapentin 600mg

No Intervention: No treatment

Patient will not be treated with preoperative gabapentin

Outcome Measures

Primary Outcome Measures

  1. Postoperative pain [Days 1-7 postoperatively]

    Amount of postoperative pain on a scale from 1-10

  2. Postoperative opioid consumption [Days 1-7 postoperatively]

    Amount of postoperative standardized opioid doses

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • adults 18 to 65 y/o without chronic gabapentin and/or opioid use
Exclusion Criteria:
  • minors less than 18 y/o, adults older than 65 y/o, chronic users of gabapentin and/or opioids, pregnant females

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Puerto Rico

Investigators

  • Principal Investigator: Angel Rivera Barrios, MD, angel.rivera56@upr.edu

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Miguel Serpa Irizarry, MD, University of Puerto Rico
ClinicalTrials.gov Identifier:
NCT05997355
Other Study ID Numbers:
  • B3650222
First Posted:
Aug 18, 2023
Last Update Posted:
Aug 18, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 18, 2023